ホーム › 尿路上皮（移行上皮）癌 › テキサス

テキサスにおける尿路上皮（移行上皮）癌の臨床試験

テキサス内の拠点で、尿路上皮（移行上皮）癌に関する38件の研究が参加者を募集しています。

テキサス内の都市

公式研究テキスト（英語）

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NEXT Austin, Austin
START Center for Clinical Research, Fort Worth
University of Texas MD Anderson Cancer Center, Houston
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #46, Austin
Exelixis Clinical Site #89, Dallas
Exelixis Clinical Site #73, Irving
他2件

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Houston Methodist San Jacinto Hospital, Baytown
Houston Methodist Cypress Hospital, Cypress
Parkland Memorial Hospital, Dallas
他10件

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06524544

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center - Conroe, Conroe
University of Texas MD Anderson Cancer Center, Houston
The University of Texas, MD Anderson Cancer Center - West Houston, Houston
他3件

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Texas Oncology, Austin
Texas Oncology - Northeast Texas, Tyler

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT07566156

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

UT Southwestern Simmons Cancer Center - RedBird, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
他1件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

UT Southwestern Medical Center, Dallas
The University of Texas M.D. Anderson Cancer Center, Houston

被験者募集中観察研究

18歳以上 · 全性別 · 2026/09/29更新 · NCT05874921

DBC-664 in Adult Patients With Solid Tumors

START San Antonio, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/29更新 · NCT07705035

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Texas Oncology - Central/South Texas, Austin
Texas Oncology - Central/South Texas, Austin
Texas Oncology - Central/South Texas, Austin
他13件

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

START Dallas Fort Worth, Fort Worth
MD Anderson, Houston
NEXT Oncology Houston, Houston
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Baylor, Scott and White Research Institute, Dallas

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

USO-Texas Oncology-Central/South Texas, Austin
World Research Link, Baytown
Parkland Health and Hospital System, Dallas
他5件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/21更新 · NCT06439836

A Study of GEN1106 in Participants With Solid Tumors

South Texas Accelerated Research Therapeutics, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/10更新 · NCT07416123

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Start - Dfw, Fort Worth
Oncology Consultants, Houston
START - San Antonio, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UPNT Research Institute, LLC, Arlington
Texas Urology Specialists-Austin, Austin
Houston Metro Urology (HMU) - Southwest Location, Houston
他3件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/03更新 · NCT06774131

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

START San Antonio, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site, Dallas

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/08/20更新 · NCT07129993

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

NEXT Oncology, Austin, Austin
NEXT Oncology, San Antonio, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/18更新 · NCT06966024

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Houston Methodist Hospital, Houston

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/17更新 · NCT04895709

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Clinical Trial Site, San Antonio

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Texas Oncology - West Texas, Amarillo
Texas Oncology, P.A., Dallas
Texas Oncology Gulf Coast, Pearland

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

The University of Texas Health Science Center at Tyler, Tyler

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Research Site, Dallas

被験者募集中第3相

18歳以上 · 全性別 · 2026/07/22更新 · NCT07720284

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Baylor Scott and White Research Institute, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Baylor Scott & White Medical Center - Temple, Temple

被験者募集中第2相

18歳以上 · 全性別 · 2026/07/22更新 · NCT04879329

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Texas Oncology - DFW, Dallas
MD Anderson Cancer Center, Houston

被験者募集中第2相

18歳以上 · 全性別 · 2026/07/10更新 · NCT06695845

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

MD Anderson Cancer Center, Houston
Next Oncology-Oncology, San Antonio

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/07/02更新 · NCT07169734

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Austin Urology Institute, Austin
UT Southwestern Medical Center, Dallas

被験者募集中

18歳〜88歳 · 全性別 · 2026/07/02更新 · NCT06394869

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

UT Southwestern Medical Center, Dallas

被験者募集中観察研究

18歳以上 · 全性別 · 2026/06/29更新 · NCT07673016

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

MDACC, Houston

被験者募集中第1相

18歳以上 · 全性別 · 2026/06/18更新 · NCT07484022

Bladder Cancer Screening Trial

University of Texas Southwestern Medical Center, Dallas

被験者募集中

50歳以上 · 全性別 · 2026/05/01更新 · NCT05646485

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

M D Anderson Cancer Center, Houston

被験者募集中

18歳以上 · 全性別 · 2026/04/15更新 · NCT04693377

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NEXT Oncology, Austin, TX 78758
NEXT Oncology, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/04/02更新 · NCT06451497

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

University of Texas Southwestern Medical Center, Dallas

被験者募集中健康なボランティア歓迎

18歳以上 · 全性別 · 2026/01/28更新 · NCT04623502

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Investigational Site, Austin
Dren Investigational Site, Dallas
Dren Investigational Site, San Antonio

被験者募集中第1相

18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston

被験者募集中第1/2相

18歳以上 · 全性別 · 2025/12/11更新 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Dallas
Massive Bio SYNERGY-AI site, Houston
Massive Bio SYNERGY-AI site, Temple

被験者募集中観察研究

全年齢 · 全性別 · 2025/10/28更新 · NCT03452774

A Study of NX-1607 in Adults With Advanced Malignancies

MD Anderson Cancer Center, Houston

被験者募集中第1相

18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。